# Gossamer Bio, Inc. (GOSS) — capital_raise [announced]
Source: SEC API (secapi.ai) · situation sit_d5b9b8f60fbac42dd589 · retrieved 2026-08-11T16:13:05.837Z

## Overview
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib, an inhaled PDGFR, CSF1R and c-KIT inhibitor, for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

On July 23, 2026, Gossamer Bio, Inc. and its subsidiaries entered into a Rights Reacquisition Agreement with Chiesi Farmaceutici S.p.A. and Chiesi USA, Inc. to terminate their May 3, 2024 Collaboration and License Agreement and reacquire worldwide development and commercial rights to seralutinib for pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), and potential future indications. Chiesi will pay Gossamer $5,000,000 within 10 days as reimbursement of outstanding development costs. In exchange, Gossamer agreed to pay Chiesi success-based milestone payments and royalties on net sales of seralutinib products up to a capped amount, after which no further royalty obligations are due.

## Terms
- Counterparty: Chiesi Farmaceutici S.p.A. and Chiesi USA, Inc. · Deal value: $5.0M · Consideration: cash

## Key dates
- Announced 2026-07-27

## Timeline
- 2026-07-27 · 8-K (0001728117-26-000064): 8-K - Gossamer Bio, Inc. — *Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib, an inhaled PDGFR, CSF1R and c-KIT inhibitor, for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.* On July 23, 2026, Gossamer Bio, Inc. and its subsidiaries entered into a Rights Reacquisition Agreement with Chiesi Farmaceutici S.p.A. and Chiesi USA, Inc. to terminate their May 3, 2024 Collaboration and License Agreement and reacquire worldwide development and commercial rights to seralutinib for pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), and potential future indications. Chiesi will pay Gossamer $5,000,000 within 10 days as reimbursement of outstanding development costs. In exchange, Gossamer agreed to pay Chiesi success-based milestone payments and royalties on net sales of seralutinib products up to a capped amount, after which no further royalty obligations are due.
  https://www.sec.gov/Archives/edgar/data/1728117/0001728117-26-000064.txt

## Citations
- 0001728117-26-000064 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000172811726000064